COVIRAN proves more effective than Sinopharm, AstraZeneca, and Sputnik

January 26, 2022 - 17:30

TEHRAN – According to a new study, the effectiveness of the Iranian-made COVIRAN Barkat vaccine in fighting the coronavirus has been more than foreign rivals, namely Sinopharm, AstraZeneca, and Sputnik.

The study was performed on 1.8 million people in Fars province from the beginning of the vaccination process till October 2021, which considered four vaccines of Sinopharm, AstraZeneca, COVIRAN, and Sputnik, Younes Panahi, the deputy minister of health for research and technology, said on Wednesday.

COVIRAN vaccine was 87 percent effective in protecting against coronavirus infection and 86 percent effective against Covid-related hospitalization, compared with 84 percent and 82 percent, respectively for AstraZeneca; Sinopharm came in third with 80 percent and 72 percent, respectively.

Russia’s Sputnik V has been the most effective in preventing mortality with 100 percent, surpassing COVIRAN, AstraZeneca, and Sinopharm percentages of 98, 92, and 86, respectively.

Made by researchers at the Headquarters for Executing the Order of the Imam, COVIRAN Barkat was unveiled on December 29, 2020, and received the license for public use on June 14.

The vaccine has proved effective against Indian strain, according to Hojjat Niki-Maleki, head of the information center of Headquarters for Executing the Order of the Imam.

Eleven countries from Asia and South America, and a European country have asked for importing COVIRAN vaccine, Hassan Jalili, the vaccine’s production manager, said in June last year.

Homegrown vaccines

Health Minister Bahram Einollahi has said five coronavirus vaccines have been so far produced domestically.

The second Iranian-made vaccine developed by the Razi Vaccine and Serum Research Institute (Razi Cov Pars) started the clinical trial on February 27.

The Iranian-Australian Spikogen vaccine joined the national vaccination process in November 2021.

Developed jointly by the Pasteur Institute of Iran and Cuba's Finlay Vaccine Institute, the Pastu Covac prevented symptomatic disease in people inoculated with three doses by 65 percent and its effectiveness in the prevention of severe disease and hospitalization was 96.5 percent.

Iran is one of the few countries that has all vaccine production platforms, Mohammad Reza Shanehsaz, former head of the Iranian Food and Drug Administration, said in June.

Meanwhile, World Health Organization (WHO) representative to Iran Jaffar Hussain said in September that the Organization was collecting the necessary information for the registration and certification of Iranian-made coronavirus vaccines.

FB/MG

 

Leave a Comment

7 + 2 =